Familial acanthosis nigricans due to K650T FGFR3 mutation

Archives of Dermatology

Volumn 143, Issue 9, 2007, Pages 1153-1156

  Berk, David R ^a   Spector, Elaine B ^b   Bayliss, Susan J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; LYSINE; THREONINE;

ACANTHOSIS NIGRICANS; ACHONDROPLASIA; ARTICLE; CASE REPORT; CODON; CROHN DISEASE; CROUZON SYNDROME; DEVELOPMENTAL DISORDER; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; FGFR3 GENE; GENE MUTATION; HETEROZYGOSITY; HUMAN; MATURITY ONSET DIABETES MELLITUS; OBESITY; PEDIGREE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEPTOR GENE; SHORT STATURE; SYNDROME; THANATOPHORIC DWARFISM;

ACANTHOSIS NIGRICANS; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; PEDIGREE; POINT MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 34548844222     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.9.1153     Document Type: Article

References (27)

1. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002;147(6):1096-1101.
2. Curth HO. Classification of acanthosis nigricans. Int J Dermatol. 1976;15(8):592-593.
3. Curth HO. Acanthosis nigricans. Birth Defects Orig Artic Ser. 1971;7(8):31-39.
4. Inamadar AC, Palit A. Generalized acanthosis nigricans in childhood. Pediatr Dermatol. 2004;21(3):277-279.
5. Curth HO, Aschner BM. Genetic studies on acanthosis nigricans. AMA Arch Derm. 1959;79(1):55-66.
6. Curth HO. Benign acanthosis nigricans. Arch Dermatol. 1967;96(5):603-604.
7. Tasjian D, Jarratt M. Familial acanthosis nigricans. Arch Dermatol. 1984;120(10):1351-1354.
8. Dhar S, Dawn G, Kanwar AJ, Nada R. Familial acanthosis nigricans. Int J Dermatol. 1996;35(2):126-127.
9. Curth HO. Benign type of acanthosis nigricans. Arch Derm Syphilol. 1936;34(3):353-366.
10. Pindborg JJ, Gorlin RJ. Oral changes in acanthosis nigricans (juvenile type): survey of the literature and report of a case. Acta Derm Venereol. 1962;42:63-71.
11. Maranon G, Alvarez Cascos M. Benign juvenile acanthosis nigricans; its relation to congenital abnormalities. Acta Derm Venereol. 1957;37(3):249-258.
12. Skiljevic DS, Nikolic MM, Jakovljevic A, Dobrosavljevic DD. Generalized acanthosis nigricans in early childhood. Pediatr Dermatol. 2001;18(3):213-216.
13. Uyttendaele H, Koss T, Bagheri B, et al. Generalized acanthosis nigricans in an otherwise healthy young child. Pediatr Dermatol. 2003;20(3):254-256.
14. Rai VM, Balachandran C. Generalized acanthosis nigricans in childhood. Dermatol Online J. 2006;12(6):14.
15. Curth HO. Significance of acanthosis nigricans. AMA Arch Derm Syphilol. 1952;66(1):80-100.
16. Taylor G, James MP, Simpson H. Familial acanthosis nigricans. J R Soc Med. 1994;87(3):169.
17. Friedman CI, Richards S, Kim MH. Familial acanthosis nigricans: a longitudinal study. J Reprod Med. 1987;32(7):531-536.
18. Chuang SD, Jee SH, Chiu HC, Chen JS, Lin JT. Familial acanthosis nigricans with madarosis. Br J Dermatol. 1995;133(1):104-108.
19. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98(6)(suppl):82S-85S.
20. Haase I, Hunzelmann N. Activation of epidermal growth factor receptor/ERK signaling correlates with suppressed differentiation in malignant acanthosis nigricans. J Invest Dermatol. 2002;118(5):891-893.
21. Logié A, Dunois-Larde C, Rosty C, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005;14(9):1153-1160.
22. Hafner C, van Oers JM, Vogt T, et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest. 2006;116(8):2201-2207.
23. Bellus GA, Spector EB, Speiser PW, et al. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet. 2000;67(6):1411-1421.
24. van Rhijn BW, van Tilborg AA, Lurkin I, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002;10(12):819-824.
25. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18-20.
26. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 2004;18(5):962-966.
27. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001;61(9):3541-3543.